GlassScriptPhysician profile
Sunil S Swami
NPI 1942441373
$4,719.71
in general payments reported to CMS, 2019-2025
28 companies · $1,403 in 2025
The $1,403 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $118 · 2021: $581 · 2022: $575 · 2023: $770 · 2024: $887 · 2025: $1,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,032 · Education: $28.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,032.16 |
| Education | $28.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,701.19 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,080.56 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Regeneron Healthcare Solutions, INC. | $311.77 | 2022-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.49 | 2019-2025 | Ofev |
| Mylan Specialty L.P. | $230.70 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $153.82 | 2024-2025 | Prolastin-C Liquid |
| Amgen INC. | $132.97 | 2023-2025 | Tezspire |
| Abbvie INC. | $99.23 | 2022-2024 | Botox |
| Pulmonx Corporation | $95.04 | 2021 | |
| Aspira Women'S Health INC | $64.83 | 2022 | |
| Verona Pharma, INC. | $59.10 | 2025 | Ohtuvayre |
| Insmed, INC. | $57.98 | 2022-2024 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $56.65 | 2021-2024 | Glassia |
| Baxter Healthcare | $51.62 | 2022 | |
| Electromed, INC. | $47.13 | 2022-2024 | Smartvest |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $42.16 | 2024 | Zerbaxa, Recarbrio, Dificid |
| United Therapeutics Corporation | $31.80 | 2025 | Tyvaso |
| Novo Nordisk INC | $31.11 | 2025 | Wegovy |
| Vapotherm INC | $24.98 | 2021 | |
| Hologic Sales and Service, LLC | $24.26 | 2025 | Aptima |
| Innovation Technologies INC | $22.89 | 2021 | |
| Sunovion Pharmaceuticals INC. | $22.63 | 2020 | |
| Sumitomo Pharma America, INC. | $21.71 | 2025 | Myfembree |
| Abbott Laboratories | $20.73 | 2022 | |
| Fisher & Paykel Healthcare INC | $19.67 | 2019 | |
| Shire North American Group INC | $15.69 | 2019 | |
| Itamar Medical INC | $14.83 | 2021 | |
| Integra Lifesciences Corporation | $14.17 | 2024 | Integra, Surgimend, Omnigraft |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Swami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.